Literature DB >> 16830000

Clinical and laboratory findings of SARS in Singapore.

Hoe-Nam Leong1, Kwai-Peng Chan, Lynette L E Oon, Evelyn S C Koay, Lee-Ching Ng, May-Ann Lee, Timothy Barkham, Mark I C Chen, Bee-Hoon Heng, Ai-Ee Ling, Yee-Sin Leo.   

Abstract

INTRODUCTION: Singapore was one of 29 countries worldwide affected by severe acute respiratory syndrome (SARS) in 2003.
MATERIALS AND METHODS: There were 238 cases identified during the outbreak. We performed a retrospective analysis of the clinical and laboratory data of 234 patients admitted to Tan Tock Seng Hospital and Singapore General Hospital.
RESULTS: The mean age of patients was 21 years, 31.6% of patients were males and 41.8% were healthcare workers. At presentation, the common symptoms were fever, myalgia, cough and headache; rhinorrhoea was uncommon. On admission, 21% had leukopenia, 18% had thrombocytopaenia, 29% had hyponatraemia, 31% had hypokalaemia, 21% had transaminitis. Polymerase chain reaction (PCR) testing of respiratory and stool samples provided the best yield at the end of the first week of illness. Thirty-two patients were initially not recognised as probable SARS and were reclassified when the serology test results were available. The chief reasons for not identifying these patients early were persistently normal chest X-rays (68.8%), very mild presentation (43.8%) and the presence of a concomitant illness (12.5%). Overall, 12% of the patients were probable SARS with atypical presentations. Overall mortality was 11.8%.
CONCLUSION: Patients infected with the SARS coronavirus had a wide clinical presentation with non-specific symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830000

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  16 in total

1.  Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.

Authors:  Qinhai Ma; Weiqi Pan; Runfeng Li; Bin Liu; Chufang Li; Yuqi Xie; Zhoulang Wang; Jin Zhao; Haiming Jiang; Jicheng Huang; Yongxia Shi; Jun Dai; Kui Zheng; Xiaobo Li; Zifeng Yang
Journal:  Pharmacol Res       Date:  2020-04-30       Impact factor: 7.658

Review 2.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  Semin Immunopathol       Date:  2017-05-02       Impact factor: 9.623

Review 3.  SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.

Authors:  Purva Asrani; Md Imtaiyaz Hassan
Journal:  Mol Cell Biochem       Date:  2020-10-16       Impact factor: 3.396

Review 4.  Epidemiology, prognosis and management of potassium disorders in Covid-19.

Authors:  Maryam Noori; Seyed A Nejadghaderi; Mark J M Sullman; Kristin Carson-Chahhoud; Ali-Asghar Kolahi; Saeid Safiri
Journal:  Rev Med Virol       Date:  2021-06-02       Impact factor: 11.043

5.  Cost-effectiveness analysis of hospital infection control response to an epidemic respiratory virus threat.

Authors:  Yock Young Dan; Paul A Tambyah; Joe Sim; Jeremy Lim; Li Yang Hsu; Wai Leng Chow; Dale A Fisher; Yue Sie Wong; Khek Yu Ho
Journal:  Emerg Infect Dis       Date:  2009-12       Impact factor: 6.883

Review 6.  Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.

Authors:  Federica Giuliani; Giulio Gualdi; Paolo Amerio
Journal:  Dermatol Ther       Date:  2020-09-14       Impact factor: 3.858

7.  Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report.

Authors:  Luyan Huang; Yiru Wang; Lisheng Wang; Yongman Lv; Qingquan Liu
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

Review 8.  COVID-19 and psoriasis: Should we fear for patients treated with biologics?

Authors:  Paolo Amerio; Francesca Prignano; Federica Giuliani; Giulio Gualdi
Journal:  Dermatol Ther       Date:  2020-05-05       Impact factor: 3.858

9.  Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).

Authors:  Li Runfeng; Hou Yunlong; Huang Jicheng; Pan Weiqi; Ma Qinhai; Shi Yongxia; Li Chufang; Zhao Jin; Jia Zhenhua; Jiang Haiming; Zheng Kui; Huang Shuxiang; Dai Jun; Li Xiaobo; Hou Xiaotao; Wang Lin; Zhong Nanshan; Yang Zifeng
Journal:  Pharmacol Res       Date:  2020-03-20       Impact factor: 7.658

10.  [Management of 90 patients presenting with suspected severe acute respiratory syndrome. Experience of a collaboration between epidemiologists and clinicians facing an emerging infectious disease health alert].

Authors:  L Cibrelus; V Nöel; J Emmanuelli; G Breton; P Longuet; B Rigolli; C Leport; J-L Vildé
Journal:  Med Mal Infect       Date:  2007-11-07       Impact factor: 2.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.